Hasseli, Rebecca and Hanses, Frank and Stecher, Melanie and Specker, Christof and Weise, Tobias and Borgmann, Stefan and Hasselberger, Martina and Hertenstein, Bernd and Hower, Martin and Hoyer, Bimba F. and Koll, Carolin and Krause, Andreas and von Lilienfeld-Toal, Marie and Lorenz, Hanns-Martin and Merle, Uta and Nunes de Miranda, Susana M. and Pletz, Mathias W. and Regierer, Anne C. and Richter, Jutta G. and Rieg, Siegbert and Roemmele, Christoph and Ruethrich, Maria M. and Schmeiser, Tim and Schulze-Koops, Hendrik and Strangfeld, Anja and Vehreschild, Maria J. G. T. and Voit, Florian and Voll, Reinhard E. and Vehreschild, Joerg Janne and Mueller-Ladner, Ulf and Pfeil, Alexander (2024) The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population-A comparison of two German registries. FRONTIERS IN MEDICINE, 11: 1332716. ISSN 2296-858X
Full text not available from this repository.Abstract
Objectives To investigate, whether inflammatory rheumatic diseases (IRD) inpatients are at higher risk to develop a severe course of SARS-CoV-2 infections compared to the general population, data from the German COVID-19 registry for IRD patients and data from the Lean European Survey on SARS-CoV-2 (LEOSS) infected patients covering inpatients from the general population with SARS-CoV-2 infections were compared. Methods 4310 (LEOSS registry) and 1139 cases (IRD registry) were collected in general. Data were matched for age and gender. From both registries, 732 matched inpatients (LEOSS registry: n = 366 and IRD registry: n = 366) were included for analyses in total. Results Regarding the COVID-19 associated lethality, no significant difference between both registries was observed. Age > 65(degrees)years, chronic obstructive pulmonary disease, diabetes mellitus, rheumatoid arthritis, spondyloarthritis and the use of rituximab were associated with more severe courses of COVID-19. Female gender and the use of tumor necrosis factor-alpha inhibitors (TNF-I) were associated with a better outcome of COVID-19. Conclusion Inflammatory rheumatic diseases (IRD) patients have the same risk factors for severe COVID-19 regarding comorbidities compared to the general population without any immune-mediated disease or immunomodulation. The use of rituximab was associated with an increased risk for severe COVID-19. On the other hand, the use of TNF-I was associated with less severe COVID-19 compared to the general population, which might indicate a protective effect of TNF-I against severe COVID-19 disease.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | inflammatory rheumatic diseases; COVID-19; general population; tumor necrosis factor-alpha inhibitors; severe disease |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Abteilung für Krankenhaushygiene und Infektiologie Medicine > Notfallambulanz |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 28 Jan 2026 07:13 |
| Last Modified: | 28 Jan 2026 07:13 |
| URI: | https://pred.uni-regensburg.de/id/eprint/65354 |
Actions (login required)
 |
View Item |
